Grit Biotechnology is a Shanghai-based cell therapy company founded in 2019 focused on developing transformative tumor-infiltrating lymphocyte (TIL) cancer treatments. Its pipeline includes GT101, described as the fastest-developing TIL therapy in China, which is slated to enter a pivotal Phase II trial by the end of 2023. The company also advances gene-edited TIL products and operates four core technology platforms central to TIL development: StemTexp®, StaViral®, KOReTIL® and ImmuT Finder®, a genome-wide CRISPR/Cas9 screening platform. GT201, a genetically engineered TIL, has an IND approved by the CFDA and has entered Phase I clinical trials. GT316 leverages ImmuT Finder®-identified targets, shows tumor elimination in PDX models with low-dose IL-2 and is in investigator-initiated trials in China. Grit plans to use new funding to support its TIL pipeline, including the pivotal Phase II for GT101 and advancement of its gene-edited TIL programs.

Total raised

$60M

Funding rounds

1

Latest round

Series B

Latest activity

Sep 2023